Opioid Use Disorder Market Size, Growth, Analysis | 2031

Opioid Use Disorder Market Size, Growth, Analysis | 2031

Segments - Opioid Use Disorder Market by Drug (Buprenorphine [Bunavail, Sublocade, Suboxone, Zubsolv, and Others], Methadone, and Naltrexone), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies & Stores), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-844 | 4.1 Rating | 66 Reviews | 190 Pages | Format : PDF Excel PPT

Report Description


The global opioid use disorder (OUD) market size was USD 3 Bn in 2022 and is likely to reach USD 8.2 Bn by 2031, expanding at a CAGR of 11.6% during 2023–2031. The market growth is attributed to the increase in the opioid epidemic in the United States, as well as the implementation of government measures to combat the epidemic.

Opioids are chemicals that interact with opioid receptors on nerve cells in the body and brain to manage pain. They can be natural or synthetically produced in laboratories to replicate the qualities of natural opioids. Prescription pain relievers, synthetic opioids, and heroin all fall within this category.

Opioid Use Disorder Market_Outlook

Acute pain such as after an injury or surgery, chronic pain, active-phase cancer therapy, palliative care, and end-of-life care are all conditions for which prescription opioids are recommended. Many patients rely on prescription opioids to help them manage their symptoms while under the supervision of a doctor.

Opioids offer a lot of positive reinforcement, which makes it more likely that people will keep taking them despite the bad repercussions. Opioid use disorder is a chronic, life-long disease with devastating implications such as impairment, relapse, and death. In many ways, opioid use disorder is similar to other drug use disorders, but it has a few distinguishing characteristics.

Opioids can cause physical dependency in as little as four to eight weeks. Stopping opioid usage abruptly causes significant symptoms in chronic users, such as generalized pain, chills, cramps, diarrhea, dilated pupils, restlessness, anxiety, nausea, vomiting, sleeplessness, and extreme cravings. Because these sensations are so intense, it is easy to feel compelled to keep using opioids to avoid withdrawal. Although there are effective therapies available, only around one out of every four patients with opioid use disorder receives specialized therapy.

Individuals with opioid use problems might benefit from medication-assisted treatment (MAT). It includes a combination of medicine, therapy, and behavioral therapy. Brain chemistry may have a role in both the cause and treatment of mental illness. As a result, drugs may be provided to aid in the modification of one's brain chemistry. Medications are also used to treat opioid cravings, and withdrawal symptoms, and to inhibit the euphoric effects of the drugs.

Opioid Use Disorder Market Dynamics

The global opioid use disorder market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.

Opioid Use Disorder Market Dynamics

  • Increasing consumption of opioids, due to the increasing prevalence of chronic diseases such as cancer, cardiovascular, pain arising from injuries, and other conditions are expected to propel the market growth during the forecast period.

  • Increasing initiatives by government and private institutes for curbing the increased consumption of opioids are anticipated to fuel the market growth in the coming years.

  • Adverse side effects associated with the administration of drugs for the treatment of opioid addiction are projected to hamper the market growth during the forecast period.

  • Lack of awareness and limited product availability presents key challenges that can hinder market expansion during the period.

  • Increased R&D activities and upcoming product launches are projected to offer lucrative opportunities for the market players.

Scope of Opioid Use Disorder Report

The global opioid use disorder market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Opioid Use Disorder Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2020–2021

Forecast Period

2023–2031

Segmentation

Drug (Buprenorphine [Bunavail, Sublocade, Suboxone, Zubsolv, and Others], Methadone, and Naltrexone), Route of Administration (Oral and Parenteral), and Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies & Stores)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Market Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

Orexo AB; Indivior PLC; Alkermes.; Titan Pharmaceuticals, Inc.; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; MediciNova, Inc.; Camurus AB; Omeros Corporation; and Collegium Pharmaceutical.

Opioid Use Disorder Market Segment Insights

Based on drug, the opioid use disorder market is segmented into buprenorphine, methadone, and naltrexone. The buprenorphine segment is further divided into bunavail, sublocade, suboxone, zubsolv, and others.

The buprenorphine segment is expected to account for a key share of the market during the forecast period owing to increasing usage of buprenorphine-containing products such as bunavail, sublocade, suboxone, and zubsolv. Suboxone is the most commonly prescribed medicine for opioid use disorder treatment, owing to its great effectiveness, few side effects, and advantageous formulary coverage.

The sublocade segment is anticipated to expand at a rapid pace during the forecast period. Buprenorphine and the Atrigel delivery system are combined in a pre-filled syringe in drug-device combination therapy. Sublocade overcomes the constraints of existing therapies by substituting an injection for daily oral drugs, making diversion and abuse more difficult while also enhancing the quality of life.

Opioid Use Disorder Market_Drug

On the basis of route of administration, the market is divided into oral and parenteral. The parenteral segment is projected to register a considerable CAGR during the forecast period, owing to the several types of OUD dosages in the parenteral form. These parenteral forms are intended for administration as an infusion or injection.

Based on distribution channel, the opioid use disorder market is segregated into hospital pharmacies, online pharmacies, and retail pharmacies & stores. The hospital pharmacies segment is expected to register a robust growth rate during the forecast period, owing to the increasing number of hospital pharmacies. The dependency of the patient population for the administration of the parenteral OUD drugs.

In terms of region, the global opioid use disorder market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period, due to the increasing number of product launches and product approval for OUD. The regional market growth can be attributed to the presence of the key player, favorable initiatives by governments, and a wide range of product offerings by key players. Several initiatives are being implemented by governments to combat the situation.

Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to increased acceptance of new products and an increase in the prevalence of opioid use disorder. Furthermore, the growing patient population and increasing healthcare expenditure in this region are projected to drive the opioid use disorder market growth.

Opioid Use Disorder Market_Region

Segments

The global opioid use disorder market has been segmented on the basis of

Drug

  • Buprenorphine
  • Bunavail
  • Sublocade
  • Suboxone
  • Zubsolv
  • Others
  • Methadone
  • Naltrexone

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies & Stores

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Orexo AB
  • Indivior PLC
  • Alkermes.
  • Titan Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries Ltd.
  • MediciNova, Inc.
  • Camurus AB
  • Omeros Corporation
  • Collegium Pharmaceutical

Competitive Landscape

Key players competing in the market are Orexo AB; Indivior PLC; Alkermes.; Titan Pharmaceuticals, Inc.; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; MediciNova, Inc.; Camurus AB; Omeros Corporation; and Collegium Pharmaceutical.

These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.

  • In March 2022, Collegium Pharmaceutical announced that it has completed the acquisition of BioDelivery Sciences International Inc. This acquisition is a major step forward to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions.
  • In February 2021, Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of modia. This product is a digital therapeutic designed for individuals with opioid use disorder (OUD).
Opioid Use Disorder Market_Key Players

Frequently Asked Questions

Some of the key global opioid use disorder market players are Orexo AB; Indivior PLC; Alkermes.; Titan Pharmaceuticals, Inc.; Hikma Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; MediciNova, Inc.; Camurus AB; Omeros Corporation; and Collegium Pharmaceutical.

For region analysis, North America dominates the global opioid use disorder market during the forecast period.

The global opioid use disorder market is estimated to register a compound annual growth rate (CAGR) of around 11.6% during the forecast period.

The global opioid use disorder market size was valued at around USD 3 billion in 2022 and is likely to reach USD 8.2 billion by 2031.

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioid Use Disorder Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Opioid Use Disorder Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Opioid Use Disorder Market - Supply Chain
  4.5. Global Opioid Use Disorder Market Forecast
     4.5.1. Opioid Use Disorder Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Opioid Use Disorder Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Opioid Use Disorder Market Absolute $ Opportunity
5. Global Opioid Use Disorder Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Opioid Use Disorder Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Opioid Use Disorder Demand Share Forecast, 2019-2026
6. North America Opioid Use Disorder Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Opioid Use Disorder Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Opioid Use Disorder Demand Share Forecast, 2019-2026
7. Latin America Opioid Use Disorder Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Opioid Use Disorder Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Opioid Use Disorder Demand Share Forecast, 2019-2026
8. Europe Opioid Use Disorder Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Opioid Use Disorder Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Opioid Use Disorder Demand Share Forecast, 2019-2026
9. Asia Pacific Opioid Use Disorder Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Opioid Use Disorder Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Opioid Use Disorder Demand Share Forecast, 2019-2026
10. Middle East & Africa Opioid Use Disorder Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Opioid Use Disorder Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Opioid Use Disorder Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Opioid Use Disorder Market: Market Share Analysis
  11.2. Opioid Use Disorder Distributors and Customers
  11.3. Opioid Use Disorder Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Orexo AB
     11.4.2. Indivior PLC
     11.4.3. Alkermes.
     11.4.4. Titan Pharmaceuticals, Inc.
     11.4.5. Hikma Pharmaceuticals PLC
     11.4.6. Teva Pharmaceutical Industries Ltd.
     11.4.7. MediciNova, Inc.
     11.4.8. Camurus AB
     11.4.9. Omeros Corporation
     11.4.10. Collegium Pharmaceutical

Methodology

Our Clients

Microsoft
General Electric
General Mills
sinopec
The John Holland Group
Dassault Aviation
Nestle SA
Honda Motor Co. Ltd.